Tuesday, February 12, 2019

Nobel Prize Winner Establishes Workstation in China-Israel (Chongqing Liangjiang) Industrial Park

By Yuling Chen, EDITOR
On January 4, 2019, China-Israel (Chongqing Liangjiang) Industrial Park was officially opened. It is located at the core area of Chongqing Liangjiang New Area Shuitu High-tech Industrial Park. Focusing on the biomedical industry, it determines to become a modern industrial park integrating research and development, transformation, production, and operation.

China-Israel (Chongqing Liangjiang) Industrial Park opened on January 4, 2019. (Photo by Li Qian)

Nobel Prize Winner Sets up a Workstation in Chongqing

Chongqing Institute of Green and Intelligent Technology of Chinese Academy of Science and Arieh Warshel agreed to cooperate that day. It was Zhongguancun Medical Engineering & Transformation Platform (Chongqing) that bridged the two parties. They will build a Nobel Prize workstation named after Arieh Warshel in Liangjiang New Area. The workstation will focus on developing cooperation in fields such as structural biology and high-throughput biological information.
A source from Liangjiang New Area Management Committee said China-Israel (Chongqing Liangjiang) Industrial Park would introduce Israeli technical projects here. It also will lead the way for the internationalization of Liangjiang New Area. Next, Zhongguancun Medical Engineering & Transformation Platform (Chongqing) will jointly build international industrial parks with Germany, France, Japan, and South Korea.

The signing of 11 Israeli Projects

11 Israeli projects became the first batch to settle in the park after the Signing Ceremony. These projects involved many fields including biological pharmacy, medical equipment and instruments, diagnostic testing, medical industry platform, and medical services.
As of June 2018, Liangjiang New Area has been home to about 90 biomedical and device enterprises. And 26 among them have been put into production, with an annual output value of RMB 66 billion.
Source: CQCB










No comments:

Post a Comment